X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs TORRENT PHARMA - Comparison Results

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA TORRENT PHARMA NATCO PHARMA/
TORRENT PHARMA
 
P/E (TTM) x 13.9 44.8 31.0% View Chart
P/BV x 4.0 6.1 65.3% View Chart
Dividend Yield % 1.1 0.8 133.1%  

Financials

 NATCO PHARMA   TORRENT PHARMA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-18
TORRENT PHARMA
Mar-18
NATCO PHARMA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs1,0801,550 69.7%   
Low Rs6711,144 58.7%   
Sales per share (Unadj.) Rs592.1354.7 166.9%  
Earnings per share (Unadj.) Rs188.440.1 470.1%  
Cash flow per share (Unadj.) Rs206.364.2 321.3%  
Dividends per share (Unadj.) Rs8.2514.00 58.9%  
Dividend yield (eoy) %0.91.0 90.6%  
Book value per share (Unadj.) Rs833.6273.1 305.2%  
Shares outstanding (eoy) m36.90169.22 21.8%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x1.53.8 39.0%   
Avg P/E ratio x4.633.6 13.8%  
P/CF ratio (eoy) x4.221.0 20.2%  
Price / Book Value ratio x1.14.9 21.3%  
Dividend payout %4.434.9 12.5%   
Avg Mkt Cap Rs m32,311227,897 14.2%   
No. of employees `0004.814.7 32.9%   
Total wages/salary Rs m3,25611,353 28.7%   
Avg. sales/employee Rs Th4,522.54,083.0 110.8%   
Avg. wages/employee Rs Th674.0772.3 87.3%   
Avg. net profit/employee Rs Th1,439.0461.3 311.9%   
INCOME DATA
Net Sales Rs m21,84860,021 36.4%  
Other income Rs m4042,988 13.5%   
Total revenues Rs m22,25263,009 35.3%   
Gross profit Rs m9,28413,493 68.8%  
Depreciation Rs m6624,086 16.2%   
Interest Rs m1543,085 5.0%   
Profit before tax Rs m8,8729,310 95.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,9202,529 75.9%   
Profit after tax Rs m6,9526,781 102.5%  
Gross profit margin %42.522.5 189.0%  
Effective tax rate %21.627.2 79.7%   
Net profit margin %31.811.3 281.6%  
BALANCE SHEET DATA
Current assets Rs m21,30752,623 40.5%   
Current liabilities Rs m5,92052,022 11.4%   
Net working cap to sales %70.41.0 7,027.6%  
Current ratio x3.61.0 355.8%  
Inventory Days Days73120 61.3%  
Debtors Days Days10776 139.7%  
Net fixed assets Rs m14,98685,016 17.6%   
Share capital Rs m369846 43.6%   
"Free" reserves Rs m30,35345,376 66.9%   
Net worth Rs m30,76046,222 66.5%   
Long term debt Rs m041,115 0.0%   
Total assets Rs m37,151142,432 26.1%  
Interest coverage x58.64.0 1,458.7%   
Debt to equity ratio x00.9 0.0%  
Sales to assets ratio x0.60.4 139.6%   
Return on assets %19.16.9 276.1%  
Return on equity %22.614.7 154.0%  
Return on capital %29.314.2 206.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,32214,580 70.8%   
Fx outflow Rs m2,9783,600 82.7%   
Net fx Rs m7,34310,980 66.9%   
CASH FLOW
From Operations Rs m4,6368,942 51.8%  
From Investments Rs m-11,155-47,070 23.7%  
From Financial Activity Rs m6,50934,174 19.0%  
Net Cashflow Rs m-18-3,655 0.5%  

Share Holding

Indian Promoters % 52.0 71.5 72.8%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 7.0 111.7%  
FIIs % 16.6 12.6 132.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 8.8 295.5%  
Shareholders   25,395 26,511 95.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   JUBILANT LIFE SCIENCES  PANACEA BIOTECH  WOCKHARDT LTD.  NOVARTIS  PLETHICO PHARMA  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Related Views on News

NATCO PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 115.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 115.2% YoY). Sales on the other hand came in at Rs 5 bn (up 27.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Nov 16, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS